Fig. 3

Clinical significance and expression control of the SRTs in primary liver cancer. a. Unsupervised clustering of patient samples based on the expression profiles of the HCC SRTs. b. Kaplan-Meier curves illustrating overall survival in SRT-high (red) and SRT-low (green) patients in the TCGA-LIHC cohort. c-e. Differences in the expression of immune checkpoint inhibitors between the SRT-high and SRT-low groups. Statistical significance between the two groups was determined using the Wilcoxon rank-sum test. FC, fold change (High Versus Low). f. Enrichment of ChIP-seq peaks for H3K27ac and ATAC-seq peaks within 3 kb from the TSSs of HCC SRTs in HCC and HCC_NT. g. Top enriched DNA binding motifs with significant P values identified through de novo analysis of sequences within 0.5 kb from the TSSs of HCC SRTs. h. Line plots displaying ATAC-seq and ChIP-seq signals of H3K27ac, SP1, SP2, and SP5 centered at the most enriched motif of SRTs. i. GSEA of HCC SRTs. Transcripts are ranked based on the correlation between the expression of SP1 and SRTs. The Normalized Enrichment Score (NES) and FDR are provided. j. Profiles of SP1 and H3K27ac occupancy, as well as ATAC-seq peaks, at the promoter regions of CCNE1 and CCNE2 in liver cancer cell, HCC, and HCC-NT tissues. **p < 0.01, ***p < 0.001